Next-gen­er­a­tion se­quenc­ing: FDA of­fers guid­ance to stream­line path to mar­ket

The FDA on Thurs­day fi­nal­ized two guid­ance doc­u­ments re­lat­ed to next-gen­er­a­tion se­quenc­ing (NGS) and draft­ed new guid­ance on in­ves­ti­ga­tion­al in vit­ro di­ag­nos­tics (IVDs) in on­col­o­gy tri­als – all of which of­fer rec­om­men­da­tions to pro­vide test de­vel­op­ers with a more ef­fi­cient path to mar­ket.

The fi­nal­ized guid­ance doc­u­ments pro­vide NGS test de­vel­op­ers with rec­om­men­da­tions for de­sign­ing, de­vel­op­ing and val­i­dat­ing tests, as well as us­ing ge­net­ic vari­ant data­bas­es to sup­port clin­i­cal va­lid­i­ty.

Jef­frey Shuren

“The rapid adop­tion of NGS tech­nolo­gies in re­search and clin­i­cal set­tings is help­ing to iden­ti­fy count­less new ge­net­ic vari­ants. How­ev­er, in­for­ma­tion about ge­net­ic vari­ants is gen­er­al­ly stored in a man­ner that is not pub­licly ac­ces­si­ble,” ex­plained Jef­frey Shuren, di­rec­tor of FDA’s Cen­ter for De­vices and Ra­di­o­log­i­cal Health. “To­day’s re­lease of the FDA’s fi­nal guid­ance on ge­net­ic vari­ant data­bas­es will help change this par­a­digm by en­cour­ag­ing da­ta shar­ing and the ac­cu­mu­la­tion in pub­lic data­bas­es of ev­i­dence sup­port­ing the clin­i­cal va­lid­i­ty of ge­nom­ic tests to help pro­vide an even more ef­fi­cient path to mar­ket.”

The 7-page draft guid­ance, mean­while, de­scribes how spon­sors of cer­tain on­col­o­gy tri­als can use an op­tion­al stream­lined sub­mis­sion process to de­ter­mine whether use of an in­ves­ti­ga­tion­al IVD — in­clud­ing those that in­cor­po­rate NGS tech­nol­o­gy — in a tri­al of in­ves­ti­ga­tion­al can­cer drug or bi­o­log­i­cal prod­ucts is con­sid­ered sig­nif­i­cant risk, non­signif­i­cant risk or ex­empt from re­view.

Scott Got­tlieb

“This is a step to­ward our goal of hav­ing a com­mon fil­ing for a drug and di­ag­nos­tic sys­tem where the drug is co-de­vel­oped with a di­ag­nos­tic test,” FDA Com­mis­sion­er Scott Got­tlieb said in re­marks on Thurs­day.

Back­ground

NGS can en­able doc­tors to look across mil­lions of DNA changes that may de­ter­mine whether a per­son has or is at risk of de­vel­op­ing a ge­net­ic dis­ease, or to in­form treat­ment de­ci­sions, FDA ex­plained.

“The rapid adop­tion of NGS-based tests in both re­search and clin­i­cal prac­tice is lead­ing to iden­ti­fi­ca­tion of an in­creas­ing num­ber of ge­net­ic vari­ants (e.g., path­o­gen­ic, be­nign, and of un­known sig­nif­i­cance), in­clud­ing rare vari­ants that may be unique to a sin­gle in­di­vid­ual or fam­i­ly,” FDA said.

To date, FDA has au­tho­rized three NGS on­co-pan­els:

  • Foun­da­tionOne CDx, which was ap­proved in No­vem­ber 2017, and can de­tect ge­net­ic mu­ta­tions in 324 genes;
  • MSK-IM­PACT, al­so ap­proved in No­vem­ber 2017, which can de­tect ge­net­ic mu­ta­tions in 468 genes; and
  • On­comine Dx Tar­get Test, ap­proved in June 2017, which can de­tect ge­net­ic mu­ta­tions in 23 genes.

“Oth­er tests us­ing NGS tech­nol­o­gy au­tho­rized by FDA to date in­clude: Prax­is Ex­tend­ed RAS Pan­el (de­tects two genes) and Foun­da­tion­Fo­cus BR­CA (al­so de­tects two genes),” an FDA spokesper­son told Fo­cus.

“These pan­els can ac­cel­er­ate can­cer drug de­vel­op­ment and im­prove clin­i­cal out­comes by re­duc­ing pa­tient screen­ing time and costs. These tech­nolo­gies can help re­duce the risks as­so­ci­at­ed with the need for mul­ti­ple tis­sue biop­sies. And these plat­forms can be rapid­ly up­dat­ed to de­tect new onco­genes or gene vari­ants as these mark­ers are iden­ti­fied by re­searchers,” Got­tlieb ex­plained.

In 2017, FDA al­so took sev­er­al ac­tions to stream­line the de­vel­op­ment and re­view of a va­ri­ety of ge­net­ic-based tests – au­tho­riz­ing a third-par­ty op­tion for au­tho­riz­ing tu­mor pro­fil­ing tests, and out­lin­ing stan­dard­ized de­vel­op­ment cri­te­ria for con­sumer car­ri­er screen­ing tests to al­low for their mar­ket­ing with­out pri­or agency re­view. FDA al­so es­tab­lished such cri­te­ria for ge­net­ic health risk tests and pro­posed to al­low their mar­ket­ing af­ter a one-time agency re­view.

Fi­nal Guid­ance

One 41-page guid­ance fi­nal­ized Thurs­day, known as “Con­sid­er­a­tions for De­sign, De­vel­op­ment, and An­a­lyt­i­cal Val­i­da­tion of Next Gen­er­a­tion Se­quenc­ing (NGS)–Based In Vit­ro Di­ag­nos­tics (IVDs) In­tend­ed to Aid in the Di­ag­no­sis of Sus­pect­ed Germline Dis­eases,” pro­vides rec­om­men­da­tions for de­sign­ing, de­vel­op­ing and val­i­dat­ing NGS-based tests.

The guid­ance of­fers per­spec­tive on what the agency looks for in pre­mar­ket sub­mis­sions to de­ter­mine a test’s an­a­lyt­i­cal va­lid­i­ty, in­clud­ing how well the test de­tects the pres­ence or ab­sence of a ge­nom­ic change.

The oth­er 16-page guid­ance is­sued Thurs­day, ti­tled “Use of Pub­lic Hu­man Ge­net­ic Vari­ant Data­bas­es to Sup­port Clin­i­cal Va­lid­i­ty for Ge­net­ic and Ge­nom­ic-Based In Vit­ro Di­ag­nos­tics,” de­scribes how test de­vel­op­ers may re­ly on clin­i­cal ev­i­dence from FDA-rec­og­nized pub­lic data­bas­es to sup­port clin­i­cal claims.

The guid­ance de­scribes how prod­uct de­vel­op­ers can use these data­bas­es to sup­port the clin­i­cal val­i­da­tion of NGS tests that they are de­vel­op­ing. These pub­lic data­bas­es may in­clude re­sources like Clin­Gen, which is main­tained by the Na­tion­al In­sti­tutes of Health (NIH). Us­ing FDA-rec­og­nized data­bas­es will pro­vide test de­vel­op­ers with an ef­fi­cient path for mar­ket­ing clear­ance or ap­proval of a new test.

On 26 April, FDA will hold a we­bi­nar on the two fi­nal guid­ance doc­u­ments.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion. 

Author

Zachary Brennan

managing editor, RAPS

The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

AstraZeneca paid a hefty price to partner with Daiichi Sankyo on their experimental antibody drug conjugate for HER2 positive breast cancer. And they’ve been rewarded with a fast ride through the FDA, with a straight shot at creating another blockbuster oncology franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.

Sean Parker, AP

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-profile debut effort in the wave of activity forming around cell therapy 2.0. It’s another appealing Bay Area group that’s attracted some of the top hands in the business to a multi-year effort to create a breakthrough. And they have $85 million in hand to make that first big step to the clinic.

Today it’s Ken Drazan and the team at South San Francisco-based ArsenalBio that are coming from behind the curtain for a public bow, backed by billionaire Sean Parker and a collection of investors that includes Beth Seidenberg’s new venture investment operation based in LA.
Drazan — a J&J Innovation vet with a long record of entrepreneurial endeavors — exited the stage in 2018 when his last mission ended as he stepped aside as president of Grail. It wasn’t long, though, before he was helping out with a business plan for ArsenalBio that revolved around the work of a large group of interconnected scientists supported by the Parker Institute for Cancer Immunology.
The biotech started by putting together an “arsenal” of technologies aimed at making cell therapies for cancer much, much better than the rather crude first-generation drugs that hit the market from Novartis and Kite.
Their drugs have become the baseline against which all others are being measured.
“The technology set we’re developing is independent of the chassis,” Drazan tells me. “It doesn’t have to be autologous (extracted from the patient) or allogeneic (off the shelf). It doesn’t have to be a T cell, it could be a B cell.” But they are starting out on the autologous side, where they have the most knowledge and insight into manufacturing techniques.
It also doesn’t have to be close to the clinic.
Drazan expects the biotech will be working its way through preclinical operations for “a few years,” with enough money from the $85 million launch round to get into humans.
By today’s superheated fundraising standards, that’s not a huge amount of cash. Lyell, another cell therapy 2.0 startup we featured last week, raised $600 million in a year, including a big chunk of cash from GlaxoSmithKline. Drazan is interested in dealmaking as well, but he also knows he has the cash necessary to support the company for a good run — a key part of what it takes to bring together a stellar team of top players.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.

Eli Lil­ly’s first PhI­II show­down for their $1.6B can­cer drug just flopped — what now?

When Eli Lilly plunked down $1.6 billion in cash to acquire Armo Biosciences a little more than a year ago, the stars seemed aligned in its favor. The jewel in the crown they were buying was pegilodecakin, which had cleared the proof-of-concept stage and was already in a Phase III trial for pancreatic cancer.

And that study just failed.

Lilly reported this morning that their cancer drug flopped on overall survival when added to FOLFOX (folinic acid, 5-FU, oxaliplatin), compared to FOLFOX alone among patients suffering from advanced pancreatic cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.

Swamy Vijayan. Plexium

San Diego up­start de­buts dis­cov­ery en­gine that puts a twist to pro­tein degra­da­tion

For years, the idea of protein degradation — utilizing the cell’s natural garbage disposal system to mark problematic proteins for destruction — remained an elegant but technically difficult concept. But now established as a promising clinical strategy, with major biopharma players such as Bayer, Gilead and Vertex trying to grab a foothold via partnership deals, a San Diego startup is looking to exploit it and push its limits.

CSL ac­cus­es ri­val Pharm­ing of par­tic­i­pat­ing in a scheme to rip off IP on HAE while re­cruit­ing se­nior R&D staffer

Pharming has landed in the middle of a legal donnybrook after recruiting a senior executive from a rival R&D team at CSL. The Australian pharma giant slapped Pharming with a lawsuit alleging that the Dutch biotech’s new employee, Joseph Chiao, looted a large cache of proprietary documents as he hit the exit. And they want it all back.
Federal Judge Juan Sanchez in the Eastern District Pennsylvania court issued an injunction on Tuesday prohibiting Chiao from doing any work on HAE or primary immune deficiency in his new job and demanding that he return any material from CSL that he may have in his possession. And he wants Pharming to tell its employees not to ask for any information on the forbidden topics.
For its part, Pharming fired off an indignant response this morning denying any involvement in extracting any kind of IP from CSL, adding that it’s cooperating in the internal probe that CSL has underway.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

UP­DAT­ED: Alex­ion pays $930M to buy out Achillion and its promis­ing com­pan­ion drug to Soliris

After a series of stock-crunching setbacks over the years, Achillion enjoyed a turn in the sun a few weeks ago as the FDA blessed their lead drug danicopan (ACH-4471) — a complementary therapy for PNH patients taking Alexion’s Soliris — with a breakthrough drug designation after taking a look at some solid supporting Phase II data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,300+ biopharma pros reading Endpoints daily — and it's free.

The $102B club: The top 15 R&D spenders in the glob­al bio­phar­ma busi­ness — 2019 edi­tion

Over the past few years, the deluge of capital into biotech has helped lead to a dramatic shift in focus on new drug approvals, as startups are now able to raise enough cash to get through a pivotal and onto the market. But the top 15 players still account for $102 billion in spending, and their successes and failures continue to determine just how productive the industry is.

Recently we’ve seen a number of new R&D chiefs take their places at the Big 15, either setting the stage for a more focused R&D strategy — often playing more heavily in oncology. That’s true for AstraZeneca, which has had some landmark successes, and GSK, which is in search of its own turnaround in pharma R&D. HIV and vaccines are separate from that group, now led by Hal Barron.

I’ve made a point of watching their track record every year for more than a decade now. What follows is intended as a broad gauge of their activity. You don’t have to have a lot of major successes to score a winning record here, but it’s virtually impossible without a blockbuster or three in the pipeline.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.